Market Overview

UPDATE: Piper Jaffray Cuts PT to $27 on Impax Laboratories on Rytary Launch Visibility

Related IPXL
Benzinga's Top Initiations
Impax Receives FDA Approval for Generic Version of Intuniv Extended-Release Tablets, 1 mg, 2 mg, 3 mg and 4 mg
Vertex Pharmaceuticals Has Great Upside Potential (Seeking Alpha)

Piper Jaffray maintained Impax Laboratories (NASDAQ: IPXL) with an Overweight rating and lowered the price target from $29.00 to $27.00.

Piper Jaffray commented, "With a compelling net cash position of now close to $460M... in the context of a $1.3B market cap and 2013 operating cash flows pushing the cash position well north of $7 per share (near 40% of IPXL's market cap), we believe the risk/reward profile of IPXL shares is attractive. We reiterate our Overweight rating and are lowering our PT to $27 from $29. … We have lowered our price target from $29 to $27 based on 20x (up from 14x) our 2015E EPS of $1.61 (previously 2014E EPS of $2.06), discounted by 20% for 1 year (previously undiscounted) … given the continued uncertainty regarding the timing of a warning letter resolution and subsequent launches of Rytary and several key generic products."

Impax Laboratories closed at $19.62 on Monday.

Latest Ratings for IPXL

Jan 2016JP MorganInitiates Coverage onNeutral
Oct 2015BTIG ResearchInitiates Coverage onBuy
Sep 2015NomuraInitiates Coverage onNeutral

View More Analyst Ratings for IPXL
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings


Related Articles (IPXL)

View Comments and Join the Discussion!

Get Benzinga's Newsletters